200 related articles for article (PubMed ID: 15228258)
21. Leishmania species, drug unresponsiveness and visceral leishmaniasis in Bihar, India.
Thakur CP; Dedet JP; Narain S; Pratlong F
Trans R Soc Trop Med Hyg; 2001; 95(2):187-9. PubMed ID: 11355558
[TBL] [Abstract][Full Text] [Related]
22. Chronic Arsenic Exposure and Risk of Post Kala-azar Dermal Leishmaniasis Development in India: A Retrospective Cohort Study.
Das S; Mandal R; Rabidas VN; Verma N; Pandey K; Ghosh AK; Kesari S; Kumar A; Purkait B; Lal CS; Das P
PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005060. PubMed ID: 27776123
[TBL] [Abstract][Full Text] [Related]
23. Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis.
Gebreyohannes EA; Bhagvathula AS; Abegaz TM; Seid MA
Infect Dis Poverty; 2018 Oct; 7(1):108. PubMed ID: 30340519
[TBL] [Abstract][Full Text] [Related]
24. Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.
Musa A; Khalil E; Hailu A; Olobo J; Balasegaram M; Omollo R; Edwards T; Rashid J; Mbui J; Musa B; Abuzaid AA; Ahmed O; Fadlalla A; El-Hassan A; Mueller M; Mucee G; Njoroge S; Manduku V; Mutuma G; Apadet L; Lodenyo H; Mutea D; Kirigi G; Yifru S; Mengistu G; Hurissa Z; Hailu W; Weldegebreal T; Tafes H; Mekonnen Y; Makonnen E; Ndegwa S; Sagaki P; Kimutai R; Kesusu J; Owiti R; Ellis S; Wasunna M
PLoS Negl Trop Dis; 2012; 6(6):e1674. PubMed ID: 22724029
[TBL] [Abstract][Full Text] [Related]
25. Experience with amphotericin B in sodium stibogluconate--unresponsive cases of visceral Leishmaniasis in north Bihar.
Giri OP; Singh AN
J Assoc Physicians India; 1994 Sep; 42(9):690-1. PubMed ID: 7883660
[TBL] [Abstract][Full Text] [Related]
26. Comparison of treatment regimens of kala-azar based on culture & sensitivity of amastigotes to sodium antimony gluconate.
Thakur CP; Thakur S; Narayan S; Sinha A
Indian J Med Res; 2008 Jun; 127(6):582-8. PubMed ID: 18765878
[TBL] [Abstract][Full Text] [Related]
27. Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis).
Thakur CP
Trans R Soc Trop Med Hyg; 1984; 78(3):391-8. PubMed ID: 6087515
[TBL] [Abstract][Full Text] [Related]
28. Expression profiling of Sudanese visceral leishmaniasis patients pre- and post-treatment with sodium stibogluconate.
Salih MAM; Fakiola M; Lyons PA; Younis BM; Musa AM; Elhassan AM; Anderson D; Syn G; Ibrahim ME; Blackwell JM; Mohamed HS
Parasite Immunol; 2017 Jun; 39(6):. PubMed ID: 28370072
[TBL] [Abstract][Full Text] [Related]
29. Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani.
Sinha R; Roychoudhury J; Palit P; Ali N
Antimicrob Agents Chemother; 2015 Jan; 59(1):344-55. PubMed ID: 25367907
[TBL] [Abstract][Full Text] [Related]
30. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic.
Sundar S; More DK; Singh MK; Singh VP; Sharma S; Makharia A; Kumar PC; Murray HW
Clin Infect Dis; 2000 Oct; 31(4):1104-7. PubMed ID: 11049798
[TBL] [Abstract][Full Text] [Related]
31. Royal Society of Tropical Medicine and Hygiene joint meeting with Médecins Sans Frontières at Manson House, London, 20 March 2003: field research in humanitarian medical programmes. Médecins Sans Frontières interventions against kala-azar in the Sudan, 1989-2003.
Ritmeijer K; Davidson RN
Trans R Soc Trop Med Hyg; 2003; 97(6):609-13. PubMed ID: 16134257
[TBL] [Abstract][Full Text] [Related]
32. A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan.
Mueller M; Balasegaram M; Koummuki Y; Ritmeijer K; Santana MR; Davidson R
J Antimicrob Chemother; 2006 Oct; 58(4):811-5. PubMed ID: 16916865
[TBL] [Abstract][Full Text] [Related]
33. Combination therapy in Kala-azar.
Singh NK; Jha TK; Singh IJ; Jha S
J Assoc Physicians India; 1995 May; 43(5):319-20. PubMed ID: 9081958
[TBL] [Abstract][Full Text] [Related]
34. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment.
Musa AM; Khalil EA; Mahgoub FA; Elgawi SH; Modabber F; Elkadaru AE; Aboud MH; Noazin S; Ghalib HW; El-Hassan AM;
Trans R Soc Trop Med Hyg; 2008 Jan; 102(1):58-63. PubMed ID: 17963805
[TBL] [Abstract][Full Text] [Related]
35. Changing Epidemiology: A New Focus of Kala-azar at High-Altitude Garhwal Region of North India.
Kumar Bhat N; Ahuja V; Dhar M; Ahmad S; Pandita N; Gupta V; Chandra S
J Trop Pediatr; 2017 Apr; 63(2):104-108. PubMed ID: 27582128
[TBL] [Abstract][Full Text] [Related]
36. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
[TBL] [Abstract][Full Text] [Related]
37. Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia.
Ostyn B; Hasker E; Dorlo TP; Rijal S; Sundar S; Dujardin JC; Boelaert M
PLoS One; 2014; 9(6):e100220. PubMed ID: 24941345
[TBL] [Abstract][Full Text] [Related]
38. Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.
Rijal S; Ostyn B; Uranw S; Rai K; Bhattarai NR; Dorlo TP; Beijnen JH; Vanaerschot M; Decuypere S; Dhakal SS; Das ML; Karki P; Singh R; Boelaert M; Dujardin JC
Clin Infect Dis; 2013 Jun; 56(11):1530-8. PubMed ID: 23425958
[TBL] [Abstract][Full Text] [Related]
39. PCR for diagnosis and assessment of cure in kala-azar patients in Bangladesh.
Salam MA; Mondal D; Kabir M; Ekram AR; Haque R
Acta Trop; 2010 Jan; 113(1):52-5. PubMed ID: 19769932
[TBL] [Abstract][Full Text] [Related]
40. Use of the polymerase chain reaction to assess the success of visceral leishmaniasis treatment.
Osman OF; Oskam L; Zijlstra EE; el-Hassan AM; el-Naeim DA; Kager PA
Trans R Soc Trop Med Hyg; 1998; 92(4):397-400. PubMed ID: 9850390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]